These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7497859)

  • 1. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences.
    Lassmann-Vague V; Belicar P; Raccah D; Vialettes B; Sodoyez JC; Vague P
    Diabetes Care; 1995 Apr; 18(4):498-503. PubMed ID: 7497859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients.
    Jeandidier N; Boullu S; Busch-Brafin MS; Chabrier G; Sapin R; Gasser F; Pinget M
    Diabetes Care; 2002 Jan; 25(1):84-8. PubMed ID: 11772906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems.
    Olsen CL; Chan E; Turner DS; Iravani M; Nagy M; Selam JL; Wong ND; Waxman K; Charles MA
    Diabetes Care; 1994 Mar; 17(3):169-76. PubMed ID: 8174443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices.
    Jeandidier N; Boivin S; Sapin R; Rosart-Ortega F; Uring-Lambert B; Réville P; Pinget M
    Diabetologia; 1995 May; 38(5):577-84. PubMed ID: 7489841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal insulin absorption after long-term intraperitoneal insulin therapy.
    Scavini M; Pincelli A; Petrella G; Galimberti G; Zager PG; Torri M; Pozza G
    Diabetes Care; 1995 Jan; 18(1):56-9. PubMed ID: 7698048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study comparing blood glucose control and risk of severe hypoglycemia achieved by non-programmable versus programmable external insulin pumps.
    Catargi B; Breilh D; Gin H; Rigalleau V; Saux MC; Roger P; Tabarin A
    Diabetes Metab; 2001 Jun; 27(3):323-7. PubMed ID: 11431597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-human insulin antibodies detection by commercial enzyme-linked immunosorbent assay kit, displacement enzyme-linked immunosorbent assay and radioimmunoassay, in Thai diabetic patients.
    Tandhanand-Banchuin N; Vannasaeng S; Ploybutr S; Sriussadaporn S
    Diabetes Res Clin Pract; 1993; 22(1):71-82. PubMed ID: 8137719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre trial of a programmable implantable insulin pump in type I diabetes. The Point Study II Group.
    Int J Artif Organs; 1995 Jun; 18(6):322-5. PubMed ID: 8593967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti-insulin antibodies.
    Lassmann-Vague V; Belicar P; Alessis C; Raccah D; Vialettes B; Vague P
    Diabet Med; 1996 Dec; 13(12):1051-5. PubMed ID: 8973887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering insulin 'round the clock.
    Fain JA
    Nursing; 2002 Aug; 32(8):54-6. PubMed ID: 12352854
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps.
    Schaepelynck P; Darmon P; Molines L; Jannot-Lamotte MF; Treglia C; Raccah D
    Diabetes Metab; 2011 Dec; 37 Suppl 4():S85-93. PubMed ID: 22208717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A method for assessing catheter patency in implanted pumps for long-term intraperitoneal insulin delivery.
    Scavini M; Hammarberg B; Dosio F; Torri M; Petrella G; Galimberti G; Vai S; Fazio F; Pozza G
    Artif Organs; 1997 May; 21(5):405-8. PubMed ID: 9129773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps.
    Schaepelynck Bélicar P; Vague P; Lassmann-Vague V
    Diabetes Metab; 2003 Sep; 29(4 Pt 1):344-8. PubMed ID: 14526262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High antigenicity of intraperitoneal insulin infusion via implantable devices: preliminary rat studies.
    Jeandidier N; Boullu S; Delatte E; Sapin R; Steibel J; Meyer P; Uhl C; Pinget M
    Horm Metab Res; 2001 Jan; 33(1):34-8. PubMed ID: 11280713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
    Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
    Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHICH FACTORS MAY AFFECT THE QUALITY OF LIFE IN PATIENTS WITH TYPE 1 DIABETES MELLITUS USING THE MEDTRONIC VEO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP?
    Thomakos P; Panagopoulos G; Kepaptsoglou O; Zoupas C; Mitrakou A
    Georgian Med News; 2018 Apr; (277):61-67. PubMed ID: 29745917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of insulin antibodies by radioassay and ELISA: interrelation and correlation with metabolic control in type I diabetes.
    Dib SA; Freire MB; Miranda WL; Russo EM
    Braz J Med Biol Res; 1994 May; 27(5):1167-80. PubMed ID: 8000338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes.
    Haardt MJ; Selam JL; Slama G; Bethoux JP; Dorange C; Mace B; Ramaniche ML; Bruzzo F
    Diabetes Care; 1994 Aug; 17(8):847-51. PubMed ID: 7956629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmunity and intraperitoneal insulin treatment by programmable pumps: lack of relationship.
    Lassmann-Vague V; SanMarco M; LeJeune PJ; Alessis C; Vague P; Belicar P
    Diabetes Care; 1998 Nov; 21(11):2041-4. PubMed ID: 9802775
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.
    Fineberg SE; Kawabata T; Finco-Kent D; Liu C; Krasner A
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3287-94. PubMed ID: 15741258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.